The global landscape for breast cancer diagnostics is undergoing a fundamental shift from volume-based testing to value-based precision diagnostics. According to the latest strategic analysis by Fact.MR, the market, valued at USD 5,878 million in 2025, is poised to reach USD 6,389.41 million in 2026. This trajectory is set to continue at a steady 6.9% CAGR, propelling the industry to a...
The increasing prevalence of oncology-related conditions and the global push for early intervention are driving a transformative era in medical imaging and molecular testing. The Breast Cancer Diagnostics Market was valued at USD 4.89 billion in 2024 and is expected to reach USD 10.33 billion by 2032, growing at a robust CAGR of 12.71% during the forecast...
NEWARK, DE / April 7, 2026 / The global ESR1 mutated metastatic breast cancer diagnostics market is projected to grow from USD 64.61 million in 2025 to USD 92.92 million by 2035, registering a CAGR of 3.7%. Growth is driven by the rising prevalence of ESR1 mutations in metastatic breast cancer patients, increasing adoption of precision medicine, and advancements in...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek